Transgene announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effective immediately. Formerly VP, Corporate Communication and Investor Relations at Transgene, in her new role as CFO, Lucie Larguier will be responsible for all aspects of the Company?s financial strategy, management and operations to ensure efficient delivery of Transgene?s innovative immunotherapy pipeline. Lucie succeeds Arnaud Dubarry who has stepped down to pursue other opportunities.

Already a member of the executive management committee, Lucie Larguier brings a comprehensive, cross-functional view of the Company?s operations and finances as well as a deep knowledge of Transgene?s investor base. Since 2016, Lucie has served as Director Corporate Communications and Investor Relations, reporting directly to the CEO. Lucie contributed significantly to the smooth execution of four successful securities transactions, as well as to strengthening the external visibility of Transgene.

Prior to joining Transgene, Lucie spent more than 10 years in the consultancy environment, advising companies on their corporate and financial messages, and contributed to the success of numerous securities transactions. She is a graduate of the Paris Institute of Political Studies (Sciences Po), with a Master?s degree in Communication with a minor in finance.